Cervical cancer prevention and control in women living with human immunodeficiency virus

Despite being highly preventable, cervical cancer is the fourth most common cancer and cause of cancer death in women globally. In low‐income countries, cervical cancer is often the leading cause of cancer‐related morbidity and mortality. Women living with human immunodeficiency virus (HIV)/acquired...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:CA: a cancer journal for clinicians Ročník 71; číslo 6; s. 505 - 526
Hlavní autoři: Castle, Philip E., Einstein, Mark H., Sahasrabuddhe, Vikrant V.
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Wiley Subscription Services, Inc 01.11.2021
John Wiley and Sons Inc
Témata:
Acquired immune deficiency syndrome
Africa
AIDS
Cervical cancer
Cervix
cytology
Disease prevention
Early Detection of Cancer
Female
HIV
HIV Infections - epidemiology
Human immunodeficiency virus
human immunodeficiency virus (HIV)
Human papillomavirus
human papillomavirus (HPV)
Humans
Immune response
Immune system
Immunocompromised Host
low‐income and middle‐income countries (LMICs)
Morbidity
Papillomavirus Infections
Papillomavirus Vaccines
Precancerous Conditions - therapy
prevention
Primary Prevention
Public health
Review
screening
Secondary Prevention
Uterine Cervical Neoplasms - epidemiology
Uterine Cervical Neoplasms - prevention & control
vaccination
visual inspection after acetic acid (VIA)
human papillomavirus (HPV)
cytology
screening
human immunodeficiency virus (HIV)
low-income and middle-income countries (LMICs)
visual inspection after acetic acid (VIA)
Africa
cervical cancer
prevention
vaccination
ISSN:0007-9235, 1542-4863, 1542-4863
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Despite being highly preventable, cervical cancer is the fourth most common cancer and cause of cancer death in women globally. In low‐income countries, cervical cancer is often the leading cause of cancer‐related morbidity and mortality. Women living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome are at a particularly high risk of cervical cancer because of an impaired immune response to human papillomavirus, the obligate cause of virtually all cervical cancers. Globally, approximately 1 in 20 cervical cancers is attributable to HIV; in sub‐Saharan Africa, approximately 1 in 5 cervical cancers is due to HIV. Here, the authors provide a critical appraisal of the evidence to date on the impact of HIV disease on cervical cancer risk, describe key methodologic issues, and frame the key outstanding research questions, especially as they apply to ongoing global efforts for prevention and control of cervical cancer. Expanded efforts to integrate HIV care with cervical cancer prevention and control, and vice versa, could assist the global effort to eliminate cervical cancer as a public health problem.
Bibliografie:The opinions expressed by the authors are their own, and this material should not be interpreted as representing the official viewpoint of the US Department of Health and Human Services, the National Institutes of Health, or the National Cancer Institute.
Disclosures
Mark H. Einstein was supported by the The AIDS Malignancy Consortium Grant (UM1CA121947) and the US‐Latin American‐Caribbean HIV/HPV‐Cancer Prevention Clinical Trials Network Partnership Center Grant (U54CA242639) from the National Cancer Institute/National Institutes of Health. Philip E. Castle has received human papillomavirus tests and assays for research at reduced or no cost from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corporation. Mark H. Einstein reports contracts from Johnson & Johnson, Pfizer, Inovio, AstraZeneca, and Merck (payment to institution for costs related to clinical trials); consulting fees from Papivax, Merck, PDS Biotechnologies, and Inovio (payment to institution for Dr. Einstein's time); unpaid committee work for the American Society for Colposcopy and Cervical Pathology and the Society of Gynecologic Oncology; and the National Cancer Institute and the World Health Organization provide payment for Dr. Einstein's time related to cervical cancer prevention. Vikrant V. Sahasrabuddhe had no disclosures.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Disclosures: Mark H. Einstein was supported by the The AIDS Malignancy Consortium Grant (UM1CA121947) and the US‐Latin American‐Caribbean HIV/HPV‐Cancer Prevention Clinical Trials Network Partnership Center Grant (U54CA242639) from the National Cancer Institute/National Institutes of Health. Philip E. Castle has received human papillomavirus tests and assays for research at reduced or no cost from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corporation. Mark H. Einstein reports contracts from Johnson & Johnson, Pfizer, Inovio, AstraZeneca, and Merck (payment to institution for costs related to clinical trials); consulting fees from Papivax, Merck, PDS Biotechnologies, and Inovio (payment to institution for Dr. Einstein's time); unpaid committee work for the American Society for Colposcopy and Cervical Pathology and the Society of Gynecologic Oncology; and the National Cancer Institute and the World Health Organization provide payment for Dr. Einstein's time related to cervical cancer prevention. Vikrant V. Sahasrabuddhe had no disclosures.
ISSN:0007-9235
1542-4863
1542-4863
DOI:10.3322/caac.21696